David Bottomley
Leeds Teaching Hospitals NHS Trust
Quality of lifeInternal medicineRadiologyUrologySurgeryOncologyRandomized controlled trialHazard ratioExternal beam radiotherapyProstateBrachytherapyProstate brachytherapyProstate cancerDocetaxelImplantNuclear medicineIn patientCastration resistantRadiation therapyIodineMedicine
84Publications
20H-index
4,232Citations
Publications 82
Newest
Purpose This prospective longitudinal study quantifies health-related quality of life (HRQoL) up to 10 years following permanent iodine-125 (125I) prostate brachytherapy alone for localized prostate cancer. Material and methods In total, 120 patients completed a validated expanded prostate cancer index composite (EPIC) questionnaire pre-treatment and at 8 time points after treatment (6 weeks, 6, 10, 18 months, and 2, 3, 5, 10 years). At each time point, clinically relevant small, moderate, and s...
Source
#1Chris ParkerH-Index: 84
#2Noel W. Clarke (University of Salford)H-Index: 72
Last. Matthew R. SydesH-Index: 68
view all 48 authors...
Summary Background The optimal timing of radiotherapy after radical prostatectomy for prostate cancer is uncertain. We aimed to compare the efficacy and safety of adjuvant radiotherapy versus an observation policy with salvage radiotherapy for prostate-specific antigen (PSA) biochemical progression. Methods We did a randomised controlled trial enrolling patients with at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7–10, positive margins, or preoperative PSA ≥10 ng/mL) for...
28 CitationsSource
#1Finbar Slevin (University of Leeds)H-Index: 3
#2Samantha Hodgson (Leeds Teaching Hospitals NHS Trust)H-Index: 1
Last. Ann Henry (University of Leeds)H-Index: 31
view all 12 authors...
Abstract Introduction Isolated local recurrence of prostate cancer following primary radiotherapy or brachytherapy may be treated with focal salvage high dose rate brachytherapy, although there remains an absence of high quality evidence to support this approach. Methods Men with prostate cancer treated consecutively between 2015 and 2018 using 19 Gy in a single fraction high dose rate brachytherapy (HDR) for locally recurrent prostate cancer were identified from an institutional database. Univa...
3 CitationsSource
#1Finbar Slevin (University of Leeds)H-Index: 3
#2Sree Lakshmi Rodda (Leeds Teaching Hospitals NHS Trust)H-Index: 2
Last. Ann Henry (University of Leeds)H-Index: 31
view all 13 authors...
Source
#1Andrew Scarsbrook (Leeds Teaching Hospitals NHS Trust)H-Index: 29
#2David Bottomley (Leeds Teaching Hospitals NHS Trust)H-Index: 20
Last. Fergus V. Gleeson (University of Oxford)H-Index: 57
view all 18 authors...
Abstract Purpose Early and accurate localisation of lesions in patients with biochemical recurrence (BCR) of prostate cancer may guide salvage therapy decisions. The present study, XXX, aimed to evaluate the impact of 18F-fluciclovine on management of men with BCR of prostate cancer. Methods Men with a first episode of BCR following curative-intent primary therapy were enrolled at 6 UK sites. Patients underwent 18F-fluciclovine PET/CT according to standardised procedures. Clinicians documented m...
14 CitationsSource
#1Finbar Slevin (University of Leeds)H-Index: 3
#2Sree Lakshmi Rodda (Leeds Teaching Hospitals NHS Trust)H-Index: 2
Last. Ann Henry (University of Leeds)H-Index: 31
view all 13 authors...
Abstract Introduction There is evidence to support use of external beam radiotherapy (EBRT) in combination with both low dose rate brachytherapy (LDR–EBRT) and high dose rate brachytherapy (HDR–EBRT) to treat intermediate and high risk prostate cancer. Methods Men with intermediate and high risk prostate cancer treated using LDR–EBRT (treated between 1996 and 2007) and HDR–EBRT (treated between 2007 and 2012) were identified from an institutional database. Multivariable analysis was performed to...
4 CitationsSource
Source
#2Louise MurrayH-Index: 16
Last. A HenryH-Index: 5
view all 12 authors...
Source
Source
Source